Search

Dr. Arlene MacDougall has been appointed as Director of Research and Innovation for mental health care at St. Joseph’s Health Care London and Lawson Health Research Institute.

She will oversee and facilitate all mental health care research at both Parkwood Institute and Southwest Centre for Forensic Mental Health Care, working to develop strong local and global partnerships, engage patients and their caregivers in research activities, and foster trans-disciplinary approaches to research.

Her goal is to build on existing research strengths in mood disorders, suicide and smart technology. She also will look to develop research links between Mental Health and Parkwood Institute’s other major research programs, Cognitive Vitality and Brain Health, and Mobility and Activity.

Dr. MacDougall joined Lawson and the Department of Psychiatry at the Schulich School of Medicine & Dentistry, Western University in 2013 working with the Prevention and Early Intervention Program for Psychoses at London Health Sciences Centre. Last year she was cross appointed to the Department of Epidemiology and Biostatistics at Schulich.

“I come to this new role with a great deal of optimism, energy and enthusiasm. Parkwood Institute Research has a number of established strengths in the mental health care field as well as potential for new streams of research and innovation,” says Dr. MacDougall. “I look forward to working with researchers, staff, and patients and their supporters, as well as academic and community partners, to make Parkwood Institute a leading centre in Canada for mental health research.”

Parkwood Institute Research is a Lawson program that represents inter-disciplinary clinical research and focuses on the advancement of innovations and discoveries that directly improve patient care. 

Dr. MacDougall will continue her own program of research, which includes recovery-oriented interventions for people with serious mental illness locally and in Africa. She is leading local studies on the use of mindfulness meditation and participatory video interventions to promote recovery among youth with early psychosis. She is also leading a project based in Kenya using social businesses and a low cost psychosocial rehabilitation toolkit to create meaningful employment, promote social inclusion and support the overall functioning and recovery of people with serious mental illness in low income settings.

Most recently she has been involved in developing and leading initiatives that use social innovation approaches to tackle complex mental health system challenges both locally and globally.

At Western, she is the Director of Global MINDS (Mental Health Incubator for Disruptive Solutions) @ Western, an educational and research initiative that supports students, faculty and community stakeholders to create solutions that will reduce the global burden of mental disorders. Global MINDS is focused on innovating for low and middle income countries and for marginalized communities in Canada. Another initiative, MINDS of London-Middlesex, is working with multiple local stakeholders to collaboratively establish a social innovation lab and use collective impact approaches that will lead to solutions that address complex challenges in the local mental health system.

Dr. MacDougall began her new role on February 1, 2017 and joins Drs. Michael Borrie and Tim Doherty as Joint/Acting Beryl and Richard Ivey Research Chair in Aging, Mental Health, Rehabilitation and Recovery. She also joins Lawson’s Research Executive Committee as Assistant Director (interim) for Parkwood Institute Research, Mental Health.

Dr. Cheryl Forchuk is the recipient of the 2020 Innovation Award for her work to prevent discharges from hospital to homelessness. Throughout her career, Dr. Forchuk has been investigating potential best practice approaches to prevent homelessness in our community for a wide range of people, including those with severe mental illness, veterans, families, and youth. 

Her recent project, ‘Preventing Hospital Discharge into Homelessness: No Fixed Address Version 2 (NFAv2)’ streamlines housing and income services by bringing them into the hospital, and integrating them into a coordinated system of care.  

Research shows that when someone is housed, their use of medical and social services decreases. Safe and adequate housing is required for individuals to recover from illness. 

 Version one of this program was a great success, providing direct access to a housing advocate and Ontario Works from inpatient hospital psychiatric units in London. The No Fixed Address v2 program provides individual inpatients, at risk of becoming homeless, with housing and financial assistance while in hospital. A collaborative approach which includes the local Canadian Mental Health Association, the Salvation Army Rent Stability Bank, Ontario Works, and the City of London brings community supports to the hospital. This enables patients to recover from their illness and reduces the number who may return to the hospital. Dr. Forchuk’s use of in-depth, individual, quantitative interviews, and qualitative focus groups, allows stakeholders to voice their experiences with the program as well as capture traditional outcomes. 

“This innovative program has been so successful in London’s hospitals that the City of London has integrated the NFAv2 service within its municipal housing support programs,” explains Dr. Arlene MacDougall, Lawson Scientist and Dr. Forchuk’s nominator. “It also has the potential to be integrated across the province as the best practice in reducing homelessness in communities. Her efforts have been recognized by multiple funding agencies, and it will soon be the model for the rest of the nation to follow. Dr. Forchuk’s commitment to improve the lives and of those in our community makes her truly deserving of this award.” 

“The No Fixed Address research project is the first evaluation anywhere of a strategy that aims to reduce the number of hospital patients being discharged into homelessness,” says Dr. Forchuk. “I’m really proud of our collective efforts. We have been able to help a lot of people, and have also learned a lot throughout the course of this study.” 

Lawson associate scientist Dr. Lena Palaniyappan has won the Canadian College of Neuropsychopharmacology (CCNP)’s 2017 Young Investigator Award for outstanding contributions to the field of neuropsychopharmacology.

The Young Investigator Award is given for basic research or clinical research in alternating years. This year’s award was presented for clinical research. Scientists who have completed their post-doctoral or residency training 10 years ago or less are considered for the award.

Dr. Palaniyappan uses neuroimaging tools to study the processes that operate in the brain when patients experience symptoms of mental illness, including psychosis – repeated voices or visions (hallucinations) and disturbing thoughts (delusions). For many patients, it is not possible to prevent psychosis or reverse the condition fully. Through their research, Dr. Palaniyappan and his team are working to fully characterize the illness and create new treatments.

Recently he led a study that showed it is possible to use information from the brain’s connectivity maps to alter the chemistry of selected brain regions. The hope is that this approach can be used to target precise areas of dysfunction rather than altering the properties of the entire brain to treat psychiatric symptoms.

“Receiving this award highlights the importance of brain imaging in discovering new therapies for brain-based disorders,” says Dr. Palaniyappan. “I feel very inspired looking at the achievements of past recipients as many of them have gone on to change how we think about the brain and mind.”

Dr. Palaniyappan is the medical director of the Prevention and Early Intervention Program for Psychoses (PEPP), a community-focused mental health program located at London Health Sciences Centre (LHSC). He is also an associate professor at Western University’s Schulich School of Medicine & Dentistry.

“With the increasing sophistication of tools to understand the mysteries of the human brain and the world-renowned expertise available in London, there has never been a better time to study psychiatric disorders,” adds Dr. Palaniyappan. “I hope we will soon be able to use brain scans to provide patient-specific information on prognosis and monitor the effects of treatments.”